依帕司他联合羟苯磺酸钙治疗糖尿病周围神经病变的效果及其对氧化应激反应的影响  

Effect of epalrestat combined with calcium dobesilate on diabetes peripheral neuropathy and oxidative stress

作　　者：王金海[1] 蒋凯 韩培 孔艳华[1] 周玉森[1] Wang Jinhai;Jiang Kai;Han Pei;Kong Yanhua;Zhou Yusen(Department of Endocrine and Metabolic Diseases,People’s Hospital of Bozhou City,Bozhou 236800,China;Department of Cardiovascular Medicine,People’s Hospital of Bozhou City,Bozhou 236800,China)

机构地区：[1]安徽省亳州市人民医院内分泌代谢病科,亳州市236800 [2]安徽省亳州市人民医院心血管内科,亳州市236800

出　　处：《中华内分泌外科杂志》2023年第3期332-336,共5页Chinese Journal of Endocrine Surgery

基　　金：安徽理工大学青年科学研究基金(自然类)(QN2018128)。

摘　　要：目的探究依帕司他联合羟苯磺酸钙在糖尿病周围神经病变(diabetes peripheral neuropathy,DPN)氧化应激反应的影响。方法回顾性分析安徽省亳州市人民医院内分泌代谢病科2018年6月至2021年6月收治92例DPN患者,按治疗方式的不同分为观察组和对照组,各46例,观察组男32例,女14例,年龄(62.57±5.12)岁;对照组男34例,女12例,年龄(63.15±5.29)岁。对照组依帕司他加糖丸治疗,观察组依帕司他联合羟苯磺酸钙治疗,比较两组密歇根糖尿病神经病变量表(Michigan diabetic neuropathy score,MDNS)、密歇根神经病变筛查量表(Michigan neuropathy screening instrument,MNSI)评分、氧化应激反应[血清超氧化物歧化酶(serum superoxide dismutase,SOD)、还原型谷胱甘肽(reduced glutathione,GSH)],临床疗效、并发症及不良反应情况。采用t检验和卡方检验。结果治疗后,两组的MDNS和MNSI评分均下降,且观察组(23.49±3.73)、(8.49±1.97)分低于对照组(28.49±3.85)、(11.53±2.28)分(t=8.337、6.843,P均<0.05);治疗后,两组SOD及GSH水平较治疗前提高,且观察组(38.96±4.89)、(89.79±6.92)高于对照组(36.42±4.61)、(86.74±6.20)(t=2.563、2.226,P=0.012、0.028);观察组的临床疗效高于对照组(Z=1.592,P=0.042);观察组一年后的并发症发生率明显低于对照组(χ^(2)=4.389,P=0.036);观察组不良反应发生率略低于对照组(χ^(2)=0.155,P=0.694)。结论依帕司他联合羟苯磺酸钙治疗DPN疗效确切,可有效减少并发症,且治疗安全性高,值得临床推广应用。Objective To explore the effect of epalrestat combined with calcium dobesilate on cardiovascular and cerebrovascular diseases and oxidative stress in diabetes patients with peripheral neuropathy.Methods In a retrospective analysis,92 patients with diabetic peripheral neuropathy were admitted to the Department of Endocrinology and Metabolism Hospital of Bozhou People’s Hospital from Jun.2018 to Jun.2021,which were divided into observation group and control group according to the different treatment methods,with 46 cases in each group.The control group were treated with epalrestat.On this basis,the observation group were given calcium dobesilate combined treatment.The two groups were compared in terms of the Michigan diabetes neuropathy score(MDNS)Michigan neuropathy screening instrument(MNSI)score,oxidative stress reaction[serum superoxide dismutase(SOD),reduced glutathione(GSH)],clinical efficacy,complications and adverse reactions Using t-test and chi square test.Result After treatment,the MDNS and MNSI scores of both groups decreased,and the observation group[(23.49±3.73),(8.49±1.97)]were lower than the control group[(28.49±3.85),(11.53±2.28)](t=8.337,6.843,P<0.05);After treatment,the levels of SOD and GSH in both groups increased compared to those before treatment,and the observation group[(38.96±4.89),(89.79±6.92)]were higher than the control group those[(36.42±4.61),(86.74±6.20)](t=2.563,2.226,P=0.012,0.028);The clinical efficacy of the observation group was higher than that of the control group(Z=1.592,P=0.042);The incidence of complications in the observation group after 1 year was significantly lower than that in the control group(χ^(2)=4.389,P=0.036);The incidence of adverse reactions in the observation group was slightly lower than that in the control group(χ^(2)=0.155,P=0.694).Conclusion Epalrestat combined with calcium dobesilate is effective in the treatment of diabetes peripheral neuropathy,can effectively reduce complications,and has high treatment safety,which is worthy of clinical app

关 键 词：依帕司他 羟苯磺酸钙 糖尿病 周围神经病变 氧化应激反应 

分 类 号：R587.2[医药卫生—内分泌]